ACTEMRA® 80mg/4ml

ACTEMRA® (tocilizumab) is a biologic medication that selectively blocks the IL-6 receptor, a key player in inflammatory processes. It is used to treat various autoimmune and inflammatory conditions by reducing the overactive immune response associated with these diseases. ACTEMRA® is available in both intravenous (IV) and subcutaneous (SC) formulations, allowing flexibility in treatment administration based on patient needs and condition severity.

Main Treatment Areas

ACTEMRA® is primarily indicated for moderate to severe rheumatoid arthritis (RA) in adults who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is also used in the treatment of juvenile idiopathic arthritis (JIA) in pediatric patients and in patients with giant cell arteritis (GCA). The drug is effective in managing symptoms of these conditions by targeting and reducing inflammation, which helps alleviate pain, stiffness, and joint damage associated with RA and other inflammatory diseases.

Key Benefits

• Effective Symptom Relief: ACTEMRA® significantly reduces the symptoms of RA and other inflammatory conditions, including pain, swelling, and joint stiffness, leading to improved quality of life.
• Disease Modification: By targeting the IL-6 receptor, ACTEMRA® helps to slow disease progression and prevent joint damage in RA patients, potentially leading to better long-term outcomes.
• Flexible Administration: The availability of both IV and SC formulations offers convenience and flexibility in treatment, allowing for personalized dosing schedules and administration routes.
• Improved Functionality: Patients often experience enhanced physical functionality and reduced disability, contributing to better daily functioning and overall well-being.

Safety Information

ACTEMRA® (tocilizumab) requires careful monitoring and management due to potential risks. Patients should be regularly monitored for signs of serious infections, liver function abnormalities, and changes in blood cell counts. The drug can increase the risk of serious infections, including tuberculosis, so screening for tuberculosis before starting treatment and ongoing monitoring is crucial. ACTEMRA® may also interact with other medications, particularly those that suppress the immune system or affect liver function, necessitating full disclosure of all current medications to the healthcare provider.

Live vaccines should be avoided during treatment. The safety of ACTEMRA® during pregnancy and breastfeeding has not been well established, so women who are pregnant, plan to become pregnant, or are breastfeeding should consult their healthcare provider to weigh the risks and benefits. Regular monitoring and adherence to medical advice are essential to mitigate potential side effects and ensure safe usage.

For detailed information and guidance, refer to the prescribing information provided by the manufacturer and consult with a healthcare professional.

ACTEMRA Purchase Information

For purchasing ACTEMRA® 80 mg/4 mL through a reliable wholesale supplier, please visit our product page. To access specific wholesale prices and detailed purchasing information, users need to sign in. Our wholesale prices are structured to offer significant savings on bulk orders, ensuring you receive competitive rates. Explore our comprehensive range of options and make informed decisions for your needs efficiently.